These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21798970)

  • 1. Biologicals for rheumatoid arthritis.
    Tugwell P; Singh JA; Wells GA
    BMJ; 2011 Jul; 343():d4027. PubMed ID: 21798970
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic consequences and potential benefits.
    Fautrel B; Verstappen SM; Boonen A
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):607-24. PubMed ID: 22137927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    van Vollenhoven RF;
    Rheumatology (Oxford); 2008 Jul; 47(7):1106-7; author reply 1107. PubMed ID: 18326533
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 5. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
    Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
    Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Now that we know what's BeSt, what is good value for the money?
    Bansback N; Marra CA
    Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
    Mulherin D; Sheeran TP
    Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D; Sheeran T; Price T; Mulherin D
    Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
    Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 11. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
    Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intervention in rheumatoid arthritis.
    Vasanth LC; Paget SA
    Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):9-10, 15-7. PubMed ID: 17694189
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.